Androgen Receptor Expression In Triple-negative Breast Cancer And Its Predictive And Prognostic Value In Patients Treated With Neoadjuvant Chemotherapy

Aim To investigate the relationship between androgen receptor(AR)and neoadjuvant chemotherapy in triple negative breast cancer(TNBC)and its prognostic significance.Method Selected 68 TNBC patients who received neoadjuvant chemotherapy(TEC)and surgery,during January 2012-October 2014 in Breast Health Center,The Affiliated Hospital of Qingdao University to investigate the relationship between AR and neoadjuvant chemotherapy in TNBC patients.All patients were regularly followed at least one time.Follow-up methods included telephone follow-up,outpatient follow-up,and inpatient follow-up.The initial diagnosis of triple-negative breast cancer was the starting point for follow-up.The follow-up endpoint was tumor recurrence or metastasis.The follow-up deadline was 2017.October.Follow-up data and status of androgen receptor expression,and other data were analyzed and processed using SPSS20.0 statistical software.Result 1.Androgen Receptor Expression: In female triple negative breast cancer tissues,the positive expression rate of androgen receptors is 61.76%.2.The relationship between androgen receptor expression and general clinicopathological parameters in patients with triple-negative breast cancer: Among the patients enrolled in the study,37 patients were older than 50 years of age,including 24 patients(74.42%)with AR positive and 7 patients(22.58%)with AR negative,P<0.05.There were 30 cases of lymph node metastasis,including 14patients(46.67%)with AR positive and 16 patients(53.33%)with AR negative,P<0.05;There were 42 patients with stage TNM stage II.Among them,30 cases(71.43%)were AR positive and 12 cases(28.57%)were AR negative,P<0.05.However,there was no uniform difference in the expression level of AR between the menstrual level and the tumor diameter.3.The relationship between androgen receptor expression and efficacy of neoadjuvant chemotherapy in patients with triple negative breast cancer: Twenty-six patients had chemotherapy response to c CR,including 23 patients with AR positive(88.46%)and 3 patients with AR negative(11.54%),P<0.05;There were 30 patients with chemotherapy response to p CR,including 26patients(86.67%)with AR positive and 4 patients(13.33%)with AR negative,P<0.05.4.The relationship between androgen receptor expression and the prognosis of triple-negative breast cancer patients: Among patients with triple-negative breast cancer,patients with androgen receptor-positive patients had a 3-year DFS of 67.6%,the 3-year DFS of neoadjuvant chemotherapy for c CR-responsive TNBC patients was 80.8%,compared with 59.5% for TNBC patients who did not achieve c CR(P<0.05);The 3-year DFS of neoadjuvant chemotherapy-responsive p CR in TNBC patients was 90.9%,while 56.5% in patients with TNBC who did not achieve p CR(P<0.05);AR-positive TNBC patients had a 3-year DFS of76.2%,and AR-negative TNBC had 53.8%(P<0.05).Among patients with triple-negative breast cancer,patients with androgen receptor-positive patients had a 3-year OS of 80.9%,the3-year OS of neoadjuvant chemotherapy for c CR-responsive TNBC patients was 92.3%,compared with 73.8% for TNBC patients who did not achieve c CR(P=0.064);The 3-year OS of neoadjuvant chemotherapy-responsive p CR in TNBC patients was 93.3%,while 71.1% in patients with TNBC who did not achieve p CR(P<0.05);AR-positive TNBC patients had a3-year OS of 90.5%,and AR-negative TNBC had 65.4%(P<0.05).Conculutsion The positive expression of AR was positively correlated with the neoadjuvant chemotherapy in patients with TNBC,which may be related to the better prognosis of patients with TNBC.